Moody Lynn & Lieberson LLC Sells 17,241 Shares of Pfizer Inc. $PFE

Key Points

• Moody Lynn & Lieberson LLC has reduced its stake in Pfizer Inc. by 36.8%, selling 17,241 shares and holding 29,564 shares valued at $717,000 at the end of the recent reporting period.
• Several large investors have significantly increased their holdings in Pfizer, with Pacer Advisors Inc. boosting their stake by 856.8% and Goldman Sachs Group Inc. increasing theirs by 51.9% during the last quarter.
• Analysts have mixed views on Pfizer's stock, with a consensus rating of "Hold" and a target price averaging around $28.12, following recent upgrades and downgrades from various firms.

Moody Lynn & Lieberson LLC lowered its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 36.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,564 shares of the biopharmaceutical company's stock after selling 17,241 shares during the quarter. Moody Lynn & Lieberson LLC's holdings in Pfizer were worth $717,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Pacer Advisors Inc. boosted its holdings in shares of Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after purchasing an additional 17,957,928 shares during the last quarter. Amundi lifted its position in shares of Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after buying an additional 15,758,846 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Pfizer in the first quarter worth about $389,861,000. Goldman Sachs Group Inc. grew its holdings in Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock valued at $670,407,000 after buying an additional 9,041,990 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Pfizer by 307.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after acquiring an additional 7,581,030 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on PFE shares. Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Morgan Stanley increased their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Wall Street Zen cut shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday. Finally, Bank of America upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Trading Up 0.6%

PFE opened at $23.75 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock's 50 day moving average price is $24.55 and its 200-day moving average price is $24.12. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The stock has a market cap of $135.03 billion, a price-to-earnings ratio of 12.63, a P/E/G ratio of 0.77 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.